206
Views
20
CrossRef citations to date
0
Altmetric
Original Article

Serum β2-Microglobulin and Prognosis of Patients with Renal Cell Carcinoma

, &
Pages 479-482 | Received 25 Sep 1995, Accepted 11 Feb 1996, Published online: 08 Jul 2009
 

Abstract

β2-Microglobulin (β2-M) was analysed in serum of 145 patients with renal cell carcinoma, and serum creatinine <125 μmol/1 by a radioimmunometric method. Forty-nine (34%) patients had serum β2-M level≥3.0 mg/1. Of the patients with distal metastases 46% had elevated levels, compared with 19% with stage I disease. Serum β2-M correlated with histopathologic grade; 58% of the patients with poorly differentiated (grade 4) tumours had elevated levels compared with 18% in grade 1-2 tumours. Also tumour cell type was associated with serum β2-M; 52% of the patients with plasmic tumours had elevated levels compared with 6% in the clear cell type. In a univariate prognostic analysis elevated serum β2-M level was inversely correlated with survival time. Using a multivariate analysis the strong prognostic factors were clinical stage and tumour diameter. Weaker factors were age and cell type, whereas the prognostic value of serum β2-M disappeared. However, if tumour cell type was excluded from the analysis, serum β2-M was identified as a prognostic factor.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.